
- /
- Supported exchanges
- / US
- / RDY.NYSE
Dr. Reddy’s Laboratories Ltd ADR (RDY NYSE) stock market data APIs
Dr. Reddy’s Laboratories Ltd ADR Financial Data Overview
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Dr. Reddy’s Laboratories Ltd ADR data using free add-ons & libraries
Get Dr. Reddy’s Laboratories Ltd ADR Fundamental Data
Dr. Reddy’s Laboratories Ltd ADR Fundamental data includes:
- Net Revenue: 325 535 M
- EBITDA: 88 840 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-23
- EPS/Forecast: 0.2212
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dr. Reddy’s Laboratories Ltd ADR News

New Strong Sell Stocks for July 18th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Acadia Healthcare Company, Inc. ACHC is a provider of behavioral healthcare services. The Zacks Consensus Estimate for its c...


Asian Equities Traded in the US as American Depositary Receipts Drop in Wednesday Trading
Asian equities traded in the US as American depositary receipts were lower Wednesday morning, declin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...

Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
Asian equities traded in the US as American depositary receipts opened the week marginally lower Mon PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...

Morgan Stanley initiates coverage on Dr. Reddy's stock with Equalweight rating
Investing.com - Morgan Stanley initiated coverage on Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) with an Equalweight rating and a price target of INR1,298.00 on Monday. The research firm cited a balan...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.